TG Therapeutics, Inc.

📍 New York, United States🗓 Founded 2011👥 428 employees💰 Last funded Mar 2015
Biotechnology Research🌐 tgtherapeutics.com
Website LinkedIn
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has completed a Phase 3 program for ublituximab, an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells, to treat patients with relapsing forms of multiple sclerosis (RMS).
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2011
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United Kingdom
1
Frequently asked questions
Who invested in TG Therapeutics, Inc.?
TG Therapeutics, Inc. has 1 investors on record on gritt.io, 1 mid-stage.
When did TG Therapeutics, Inc. last raise funding?
The most recent investment in TG Therapeutics, Inc. recorded on gritt.io was in March 2015.
When was TG Therapeutics, Inc. founded?
TG Therapeutics, Inc. was founded in 2011.
What industry is TG Therapeutics, Inc. in?
TG Therapeutics, Inc. operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is TG Therapeutics, Inc. based?
TG Therapeutics, Inc. is headquartered in New York, United States.